🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the bacteria, according to health experts.

An International Health Concern

Cases of gonorrhoea are escalating worldwide, with data suggesting over 82 million new cases each year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to develop it.

“This approval represents a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Data and Worldwide Availability

Based on results detailed in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The trial included nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Doctors treating patients have expressed positive views. Having a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is deemed crucial to reduce the burden of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.